The antagonistic metabolite of GLP-1, GLP-1 (9-36)amide, does not influence gastric emptying and hunger sensations in man

References

• Holst JJ, Orskov C, Nielsen OV, Schwartz TW. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 1987; 211: 169–74
   PubMed Web of Science ®Google Scholar
• Holst JJ. Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. Trends EndocrinolMetab 1999; 10: 229–35
   PubMed Web of Science ®Google Scholar
• Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665–73
   PubMed Web of Science ®Google Scholar
• Wettergren A, Wojdemann M, Meisner S, Stadil F, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 1997; 40: 597–601
   PubMed Web of Science ®Google Scholar
• Nagell CF, Wettergren A, Pedersen JF, Mortensen D, Holst JJ. Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1. Scand J Gastroenterol 2004; 39: 353–8
   PubMed Web of Science ®Google Scholar
• Gutzwiller JP, Goke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999; 44: 81–6
   PubMed Web of Science ®Google Scholar
• Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515–20
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Glucagon-like peptides. Diabetes 1998; 47: 159–69
   PubMed Web of Science ®Google Scholar
• Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellstrom PM. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 1998; 43: 2284–2290
   PubMedGoogle Scholar
• Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126–31
   PubMed Web of Science ®Google Scholar
• Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 1996; 271: E458–64
   PubMed Web of Science ®Google Scholar
• Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829–35
   PubMedGoogle Scholar
• Knudsen LB, Pridal L. Glucagon-like peptide-1-(9-36)amide is a major metabolite of glucagon- like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996; 318: 429–35
   PubMed Web of Science ®Google Scholar
• Wettergren A, Wojdemann M, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (7-36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36)amide. Peptides 1998; 19: 877–82
   PubMedGoogle Scholar
• Deacon CF, Plamboeck A, Moller S, Holst JJ. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. Am J Physiol Endocrinol Metab 2002; 282: E873–9
   Google Scholar
• Wettergren A, Wojdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 1998; 275: G984–G92
   PubMedGoogle Scholar
• Miholic J, Orskov C, Holst JJ, Kotzerke J, Meyer HJ. Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy. Dig Dis Sci 1991; 36: 1361–70
   PubMed Web of Science ®Google Scholar
• Raben A, Tagliabue A, Astrup A. The reproducibility of subjective appetite scores [published erratum appears in Br J Nutr 1995;74:283]. Br J Nutr 1995; 73: 517–30
   PubMed Web of Science ®Google Scholar
• Pedersen JF. A modified sonographic technique for assessment of gastric emptying of liquid. Acta Radiol 2003; 44: 340–2
   PubMed Web of Science ®Google Scholar
• Hveem K, Jones KL, Chatterton BE, Horowitz M. Scintigraphic measurement of gastric emptying and ultrasonographic assessment of antral area: relation to appetite. Gut 1996; 38: 816–21
   PubMed Web of Science ®Google Scholar
• Ricci R, Bontempo I, Corazziari E, La Bella A, Torsoli A. Real time ultrasonography of the gastric antrum. Gut 1993; 34: 173–6
   PubMed Web of Science ®Google Scholar
• Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994; 43: 535–9
   PubMed Web of Science ®Google Scholar
• Orskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 1986; 119: 1467–75
   PubMed Web of Science ®Google Scholar
• Hartmann B, Johnsen AH, Orskov C, Adelhorst K, Thim L, Holst JJ. Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides 2000; 21: 73–80
   PubMed Web of Science ®Google Scholar
• Schirra J, Goke B. The physiological role of GLP-1 in humans: incretin, ileal brake or more?. Regul Pept 2005; 128: 109–15
   PubMedGoogle Scholar
• Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273: E981–8
   PubMed Web of Science ®Google Scholar
• Blazquez E, Alvarez E, Navarro M, Roncero I, Rodriguez-Fonseca F, Chowen JA, et al. Glucagon-like peptide-1 (7-36) amide as a novel neuropeptide. Mol Neurobiol 1998; 18: 157–73
   PubMedGoogle Scholar
• Hoosein NM, Gurd RS. Identification of glucagon receptors in rat brain. Proc Natl Acad Sci USA 1984; 81: 4368–72
   PubMedGoogle Scholar
• Merida E, Delgado E, Molina LM, Villanueva-Penacarrillo ML, Valverde I. Presence of glucagon and glucagon-like peptide-1-(7-36)amide receptors in solubilized membranes of human adipose tissue. J Clin Endocrinol Metab 1993; 77: 1654–7
   PubMed Web of Science ®Google Scholar
• Orskov C, Poulsen SS. Glucagonlike peptide-I-(7-36)-amide receptors only in islets of Langerhans. Autoradiographic survey of extracerebral tissues in rats. Diabetes 1991; 40: 1292–6
   PubMedGoogle Scholar
• Richter G, Goke R, Goke B, Schmidt H, Arnold R. Characterization of glucagon-like peptide-I(7-36)amide receptors of rat lung membranes by covalent cross-linking. FEBS Lett 1991; 280: 247–50
   PubMed Web of Science ®Google Scholar
• Uttenthal LO, Toledano A, Blazquez E. Autoradiographic localization of receptors for glucagon-like peptide-1 (7-36) amide in rat brain. Neuropeptides 1992; 21: 143–6
   PubMed Web of Science ®Google Scholar
• Shimizu I, Hirota M, Ohboshi C, Shima K. Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. Endocrinology 1987; 121: 1076–82
   PubMed Web of Science ®Google Scholar
• Larsen PJ, Holst JJ. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regul Pept 2005; 128: 97–107
   PubMedGoogle Scholar
• Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 1997; 273: G920–7
   PubMed Web of Science ®Google Scholar
• Nagell CF, Wettergren A, Ørskov C, Holst JJ. The inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs. Scand J Gastroenterol 2006; 41: 667–72
   PubMed Web of Science ®Google Scholar